About Us

      Provectus Algae is an Australian biotech startup specialising in the optimisation of Algae to produce high-value compounds for use in a wide array of industries and applications. 
      The groundbreaking capabilities of the Provectus Algae team are enabled by a well-balanced fusion of its proprietary innovative technology and a thorough understanding of the unique biological traits of algae.

      Executive Team


      Nusqe Spanton

      Founder & CEO

      Algae and Aquaculture expert with 15 years experience in international aquaculture production, corporate management and marine biotechnology applications for public and private companies. Passionate and motivated leader with a proven track record in complex project delivery.

      Board & Advisers


      David Williams

      Chairman, Board of Directors

      Corporate, merger and acquisitions specialist and commercial lawyer for 35+ years


      Tom Himstedt

      Non-Executive Director

      Tom is an operational executive with more than 20 years’ experience in vertically integrated food manufacturing, commercial product development and nutraceutical R&D. 


      Ryan Bethencourt

      Non-Executive Director

      Co-founder and CEO of 3 biotech companies, biotech investor and co-founder of IndieBio & Sustainable Food ventures.


      Roslyn Hendriks

      Adviser Biotechnology & Commercialisation

      Raised $40M in high risk capital. Brought medical innovations to market. Former General Manager UniQuest commercialising research.


      Garry Redlich

      Adviser Biotechnology & Technical Scale-up

      Successfully brought 2 drugs to advanced clinical development and 1 to global regulatory approval. Federal government level advisor.


      Kevin Grant

      Adviser Regulatory Requirements

      35 years principal biochemist at Therapeutic Goods Administration (TGA)

      Why Algae

      High-value algae strains are heralded as the eco super-crop of the future but they have typically been difficult to grow in commercial quantities- until now.
      We have the technology to capitalise on an existing market, mature it and be a driving force in the future of bioceuticals and aquaculture.